NCT01260298已完成不适用
Protocol To Evaluate Patient Measurements After Ultrasonic Treatment.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
研究概览
简要总结
The objective of this study is to observe body contour changes following treatment using the MC1 device.
详细描述
The purpose of this research study is to observe body contour changes following treatment using the MC1 device. The MC1 System is FDA cleared for relief of minor muscle aches, pain and muscle spasm, temporary improvement in local blood circulation, and temporary reduction in the appearance of cellulite.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Is between 20 and 50 years of age, inclusive, on the day of enrolment.
- •Has a BMI between 20 and 30 kg/m
- •Is to be treated in the infra-scapular area using the MC
- •Has never been treated with the MC1 before.
排除标准
- •Patient is lactating, has a positive pregnancy test within 7 days of planned study procedure (for female patients of child-bearing potential), or intends to become pregnant during the study or is not using effective methods to prevent pregnancy.
- •Currently enrolled in another device or drug study that has not completed the required follow-up period, or has completed all other study-required follow-up less than 30 days before enrolment in this study.
- •Keloid scars, hypertrophic scars or a history of abnormal healing.
- •Thrombophlebitis.
- •Bleeding or bruising disorders (e.g. idiopathic thrombocytopenic purpura, anticoagulated patients).
- •Tissue ischemia in the area to be treated.
- •Hypertension or abnormally high blood pressure.
- •High cholesterol.
- •Active collagen vascular disease (e.g. fibromyalgia, panniculitis, lupus etc.).
- •Tuberculosis.
- •Auxiliary electric organs (such as pacemakers), metal or myoelectric prosthesis.
- •Endocrine syndromes or thyroid hyperfunction.
- •Any type of hemorrhagic (bleeding) status.
- •Active skin infection, any infection in the treated area within the last 30 days or skin disease in the area to be treated (e.g. eczema, psoriasis, urticaria, dermographism).
- •Hepatic or renal insufficiency.
- •Bone, muscle or joint disease, dysfunction or healing in the area to be treated.
- •Malignancy in the area to be treated.
- •Laminectomy in the area to be treated. 5.
- •Withdrawal and Replacement of Subjects
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Protocol To Evaluate Patient Measurements After Ultrasonic TreatmentPatients Treated With VaserShape MC1NCT01373827Sound Surgical Technologies, LLC.7
已完成
不适用
Durolane SJ for Treatment of RhizarthrosisRhizarthrosisNCT02676284Zambon SAU36
招募中
不适用
Study Protocol to Evaluate Clinical and Imaging Results of Knee Fresh Osteochondral AllograftsOsteochondral DefectNCT04236492Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau40
Unknown
3 期
Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic ArthritisArthritis; Psoriasis (Etiology)NCT03191539Hospital Universitari Vall d'Hebron Research Institute56
招募中
不适用
Observing Physiological Changes in Patients With Long-term Oxygen TherapyChronic Respiratory DiseaseNCT06525857Insel Gruppe AG, University Hospital Bern40